|
1
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pennathur A, Farkas A, Krasinskas AM,
Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ and
Luketich JD: Esophagectomy for T1 esophageal cancer: Outcomes in
100 patients and implications for endoscopic therapy. Ann Thorac
Surg. 87:1048–1055. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edgren G, Adami HO, Weiderpass E and Nyrén
O: A global assessment of the oesophageal adenocarcinoma epidemic.
Gut. 62:1406–1414. 2013. View Article : Google Scholar
|
|
5
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar :
|
|
8
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar
|
|
9
|
Anisimov VN, Egormin PA, Piskunova TS,
Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV,
Karkach AS and Romanyukha AA: Metformin extends life span of
HER-2/neu transgenic mice and in combination with melatonin
inhibits growth of transplantable tumors in vivo. Cell Cycle.
9:188–197. 2010. View Article : Google Scholar
|
|
10
|
Zhou XZ, Xue YM, Zhu B and Sha JP: Effects
of metformin on proliferation of human colon carcinoma cell line
SW-480. Nan Fang Yi Ke Da Xue Xue Bao. 30:1935–1938. 1942.2010.(In
Chinese).
|
|
11
|
Kato K, Gong J, Iwama H, et al: The
antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi M, Kato K, Iwama H, et al:
Antitumor effect of metformin in esophageal cancer: In vitro study.
Int J Oncol. 42:517–524. 2013.
|
|
13
|
Miyoshi H, Kato K, Iwama H, et al: Effect
of the anti-diabetic drug metformin in hepatocellular carcinoma in
vitro and in vivo. Int J Oncol. 45:322–332. 2014.PubMed/NCBI
|
|
14
|
Masaki T, Tokuda M, Yoshida S, et al:
Comparison study of the expressions of myristoylated alanine-rich C
kinase substrate in hepatocellular carcinoma, liver cirrhosis,
chronic hepatitis, and normal liver. Int J Oncol. 26:661–671.
2005.PubMed/NCBI
|
|
15
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
D’Incalci M, Colombo T, Ubezio P, et al:
The combination of yondelis and cisplatin is synergistic against
human tumor xenografts. Eur J Cancer. 39:1920–1926. 2003.
View Article : Google Scholar
|
|
19
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
20
|
Bird-Lieberman EL and Fitzgerald RC: Early
diagnosis of oesophageal cancer. Br J Cancer. 101:1–6. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Solaymani-Dodaran M, Logan RF, West J,
Card T and Coupland C: Risk of oesophageal cancer in Barrett’s
oesophagus and gastro-oesophageal reflux. Gut. 53:1070–1074. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Falk GW: Barrett’s esophagus.
Gastroenterology. 122:1569–1591. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujihara S, Mori H, Kobara H, Nishiyama N,
Kobayashi M, Oryu M and Masaki T: Metabolic syndrome, obesity, and
gastrointestinal cancer. Gastroenterol Res Pract. 2012:4836232012.
View Article : Google Scholar
|
|
24
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vazquez-Martin A, Oliveras-Ferraros C and
Menendez JA: The antidiabetic drug metformin suppresses HER2
(erbB-2) oncoprotein overexpression via inhibition of the mTOR
effector p70S6K1 in human breast carcinoma cells. Cell Cycle.
8:88–96. 2009. View Article : Google Scholar
|
|
26
|
Vázquez-Martín A, Oliveras-Ferraros C, del
Barco S, Martín-Castillo B and Menéndez JA: mTOR inhibitors and the
anti-diabetic biguanide metformin: New insights into the molecular
management of breast cancer resistance to the HER2 tyrosine kinase
inhibitor lapatinib (Tykerb). Clin Transl Oncol. 11:455–459. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Masaki T, Shiratori Y, Rengifo W, et al:
Cyclins and cyclin-dependent kinases: Comparative study of
hepatocellular carcinoma versus cirrhosis. Hepatology. 37:534–543.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han S, Kim HY, Park K, Lee MS, Kim HJ and
Kim YD: Expression of p27Kip1 and cyclin D1 proteins is inversely
correlated and is associated with poor clinical outcome in human
gastric cancer. J Surg Oncol. 71:147–154. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aoyagi K, Koufuji K, Yano S, Murakami N,
Terasaki Y, Yamasaki Y, Takeda J, Tanaka M and Shirouzu K:
Immunohistochemical study on the expression of cyclin D1 and E in
gastric cancer. Kurume Med J. 47:199–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Martin-Castillo B and Menendez JA: Metformin activates an
ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like
response. Cell Cycle. 10:1499–1501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and
Xu GM: Metformin induces apoptosis of pancreatic cancer cells.
World J Gastroenterol. 14:7192–7198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ren M, Zhong X, Ma CY, Sun Y, Guan QB, Cui
B, Guo J, Wang H, Gao L and Zhao JJ: Insulin-like growth factor-1
promotes cell cycle progression via upregulation of cyclin D1
expression through the phosphatidylinositol 3-kinase/nuclear
factor-kappaB signaling pathway in FRTL thyroid cells. Acta
Pharmacol Sin. 30:113–119. 2009. View Article : Google Scholar
|
|
35
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zeng ZS, Cohen AM, Zhang ZF,
Stetler-Stevenson W and Guillem JG: Elevated tissue inhibitor of
metalloproteinase 1 RNA in colorectal cancer stroma correlates with
lymph node and distant metastases. Clin Cancer Res. 1:899–906.
1995.PubMed/NCBI
|
|
37
|
Mori M, Mimori K, Sadanaga N, Inoue H,
Tanaka Y, Mafune K, Ueo H and Barnard GF: Prognostic impact of
tissue inhibitor of matrix metalloproteinase-1 in esophageal
carcinoma. Int J Cancer. 88:575–578. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Liao JM, Zeng SX and Lu H: p53
downregulates Down syndrome-associated DYRK1A through miR-1246.
EMBO Rep. 12:811–817. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takeshita N, Hoshino I, Mori M, et al:
Serum microRNA expression profile: miR-1246 as a novel diagnostic
and prognostic biomarker for oesophageal squamous cell carcinoma.
Br J Cancer. 108:644–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tanaka M, Oikawa K, Takanashi M, Kudo M,
Ohyashiki J, Ohyashiki K and Kuroda M: Down-regulation of miR-92 in
human plasma is a novel marker for acute leukemia patients. PLoS
One. 4:e55322009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang
W, Ma Y and Xiao H: Genome-wide microRNA profiles identify miR-378
as a serum biomarker for early detection of gastric cancer. Cancer
Lett. 316:196–203. 2012. View Article : Google Scholar
|
|
42
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69(Suppl 3): 4–10. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen M, Cai E, Huang J, Yu P and Li K:
Prognostic value of vascular endothelial growth factor expression
in patients with esophageal cancer: A systematic review and
meta-analysis. Cancer Epidemiol Biomarkers Prev. 21:1126–1134.
2012. View Article : Google Scholar : PubMed/NCBI
|
